As a clinically more relevant way to inhibit PDK1 activity we included the validated PDK1 inhibitor DAP (2,2-dichloroacetophenone)38 in our studies and examined its effects on proliferation, apoptosis and leukemia development in vitro and in vivo in humanized niche xenograft mouse models. The gene discussed is PDK1; the disease is leukemia.